

PD Dr. med. Martin Sprinzi

* 24.06.1975

Specialist in internal medicine (gastroenterology, hepatology, infectiology)
Working Group Leader

I. Medical Clinic and Polyclinic
University Medical Center of the Johannes Gutenberg University Mainz
D-55131 Mainz, Langenbeckstr. 1
Tel: +49-6131-17 4406

martin.sprinzi@unimedizin-mainz.de

www.unimedizin-mainz.de/1-med/patienten/mitarbeiter/portraits/sprinzi.html



Academia

- | | |
|-----------|--|
| 2015 | Habilitation, Department of Internal Medicine, I. Med. Clinic and Polyclinic, University Medical Center of the Johannes Gutenberg University Mainz |
| 2012 | Specialist in Gastroenterology, University Medical Center of the Johannes Gutenberg University Mainz |
| 2009 | Specialist in Internal Medicine, University Medical Center of the Johannes Gutenberg University of Mainz |
| 2001 | Doctorate (Dr. med.) at the Center for Molecular Biology (H. Schaller) at the University of Heidelberg |
| 1994-2001 | Studies in human medicine, University of Heidelberg |

Career

- | | |
|------------|---|
| since 2012 | Group leader, Department of Internal Medicine, I. Med. Clinic and Polyclinic, University Medical Center of the Johannes Gutenberg University Mainz |
| since 2009 | Senior physician, Department of Internal Medicine, I. Med. Clinic and Polyclinic, University Medical Center of the Johannes Gutenberg University Mainz |
| 2010-2012 | Postdoc, Institute of Virology, TU Munich (Prof. Dr. Protzer) |
| 2002-2009 | Assistant doctor, Postdoc, Department of Internal Medicine, I. Med. Clinic and Polyclinic, University Medical Center of the Johannes Gutenberg University Mainz |

Awards

- | | |
|-------------|--|
| 2010 - 2012 | „Clinical Leave“ Scholarship of the Helmholtz Alliance for Tumor Immunotherapies at the Institute of Virology, TU Munich |
| 2010 | Annual Award of the Gastroenterological Working Group Rhineland/Palatinate (GARPS) |
| 2006 | Annual Award of the Gastroenterological Working Group Rhineland/Palatinate (GARPS) |

Memberships

- German Association for the Study of the Liver (GASL)
- German Society for Digestive and Metabolic Disorders (DGVS)
- European Association for the Study of the Liver (EASL)

Selected Publications

Labenz C, Toenges G, Schattenberg JM, Nagel M, **Sprinzi MF**, Nguyen-Tat M, Zimmermann T, Huber Y, Marquardt JU, Galle PR, Wörns MA.. Clinical Predictors for Poor Quality of Life in Patients With Covert Hepatic Encephalopathy. *J Clin Gastroenterol.* 2019 Aug;53(7):e303-e307.

Sprinzi MF, Puschnik A, Schlitter AM, Schad A, Ackermann K, Esposito I, Lang H, Galle PR, Weinmann A, Heikenwalder M, Protzer U (2015) Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion. *J Hepatol* 62:863-70

Sprinzi MF, Galle PR. Facing the dawn of immunotherapy for hepatocellular carcinoma. *J Hepatol.* 2013 Apr 6

Sprinzi MF, Reisinger F, Puschnik A, Ringelhan M, Ackermann K, Hartmann D, Schiemann M, Weinmann A, Galle PR, Schuchmann M, Friess H, Otto G, Heikenwalder M, Protzer U. Sorafenib perpetuates cellular anti-cancer effector functions by modulating the cross talk between macrophages and natural killer cells. *Hepatology.* 2013 Feb 19.

Schuchmann M, Kittner JM, Schlaak JF, Klass DM, Eisenbach C, Berg T, Trautwein C, Günther R, Zeuzem S, Gösseinger R, Ehrlich A, Neumann K, Wachtlin D, **Sprinzi MF**, Zimmermann T, Böcher WO, Galle PR. No beneficial effect of all-trans retinoic acid in previous non-responder patients with chronic hepatitis C: the ATRACTION study, a phase II randomised trial. *Dig Liver Dis.* 2013 Apr;45(4):323-9.

Sprinzi MF, Weinmann A, Lohse N, Tönissen H, Koch S, Schattenberg J, Hoppe-Lotichius M, Zimmermann T, Galle PR, Hansen T, Otto G, Schuchmann M. Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation. *Transpl Int.* 2013 Jan;26(1):67-74.